Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2014

View Archived Issues

Clearance of hepatic sphingomyelin in patients with Niemann-Pick disease type B treated with rhASM

HMOX1 genetic variations associated with severe malarial anemia

Presidio enters into two agreements for HCV NS5A inhibitor PPI-668

Boehringer Ingelheim plans phase II trial of BI-409306 in patients with schizophrenia

Novavax begins phase I trial of RSV F Vaccine in pediatric subjects

Janssen to begin phase I study of JNJ-49122944

OncoSec Medical receives grant to identify biomarkers for response to IL-12 gene therapy

Promising topline data from phase II study of tivantinib in metastatic prostate cancer

GE Healthcare and Takeda form liver fibrosis imaging collaboration

Ono Pharmaceutical reviews milestones of second quarter of fiscal 2014

Bionomics plans further clinical development of BNC-210

Results presented for a number of biomarkers of inflammatory bowel disease

Phase I results demonstrate the potential of LUM-002 in treatment of NASH

EnGeneIC initiates phase I trial of miR-16 in MPM

PBI-4050 cleared to commence trials in patients with diabetic kidney disease

AVEO Oncology enters into agreement with Ophthotech for tivozanib

Merck & Co. patents detail novel orexin antagonists

Threshold Pharmaceuticals receives FDA fast track designation for TH-302

Kissei Pharmaceutical reports development of D2 receptor agonists

iBio licenses technology to Caliber for production of Ebola virus antibodies

Japan researchers prepare and test novel anti-HB-EGF MAbs

Daiichi Sankyo patents new phosphate transporter inhibitors

Kaketsuken launches Byclot combination for intravenous injection in Japan

Czech organizations report tamoxifen derivatives

Brodalumab superior to ustekinumab in phase III trial in moderate to severe plaque psoriasis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...